Suppl Table 2.Xlsx

Total Page:16

File Type:pdf, Size:1020Kb

Suppl Table 2.Xlsx Panic, G. et al. PLOS Neglected Tropical Diseases 9, PRESENT REPORT e0003962 (2015). % Degeneracy Cpds shared with 1,323 drug set d (SRF) after 72 h Categorization Active Inactive M after 72 h current report Amoxapine 4.54 100 Acriflavinium Hydrochloride 3.61 100 1 1 Amodiaquine Dihydrochloride 3.15 81.82 Aprepitant 2.60 100 Atorvastatin Calcium 3.13 76.92 1 1 Benzalkonium Chloride 3.27 100 1 1 Benzyl Benzoate 3.34 83.33 1 1 Beta-naphthol 3.05 100 Bromhexine 2.58 100 Bromocriptine Mesylate 3.23 61.9 Butylated Hydroxyanisole 3.07 100 Chlormidazole 2.88 62.5 chloroxine 2.50 100 1 1 Clioquinol 3.38 100 Cloxyquin 2.54 100 Compactin, Mevastatin 3.51 100 Cyclandelate 2.47 100 Danazol 2.96 58.82 Desipramine 2.46 100 Dichlorophene, Dichlorophen 2.66 100 1 1 Dicyclomine 3.11 100 Digoxin 2.55 100 Disulfiram 2.75 100 1 1 Docetaxel 2.76 92.31 Ebselen 2.78 100 Erythromycin Propionate 4.08 100 Exemestane 2.94 100 Fenbendazole 2.86 100 Fenofibrate 2.78 55.56 Formoterol 2.53 100 hexetidine 3.00 100 1 1 Isobutamben 4.67 100 Ivermectin 3.10 100 d M ≥ 2.47 and Lisuride 2.51 72.73 % Mebhydrolin Naphthalenesulfonate 3.59 72 degeneracy >50 Medroxyprogesterone 2.91 100 Mitotane 3.10 100 Mitoxantrone 4.67 75 Naftopidil Dihydrochloride, Naftopidil 7.29 70.83 nifuroxazide 2.63 100 1 1 Ouabain 3.14 71.43 perhexiline 2.72 100 1 1 Pitavastatin Calcium 4.97 78.26 primaquine 3.25 91.67 1 1 Proflavine Hemisulfate 2.47 100 Promazine 2.52 100 1 1 Propofol 3.08 100 Pyrvinium Pamoate 2.67 100 1 1 Rapamycin 3.64 68.18 reserpine 2.64 60 1 1 Rimantadine 2.51 100 Salinomycin, Sodium 2.51 100 1 1 Sanguinarine Chloride, Sanguinarine Sulfate 3.45 100 1 1 securinine 2.77 100 1 1 Simvastatin 2.49 100 1 1 suloctidil 2.98 100 1 1 Sunitinib Malate 2.85 100 thioridazine 3.32 100 1 1 Thonzonium Bromide 2.90 69.57 Tilorone 2.93 100 Tioconazole 2.48 100 Triclosan 2.63 100 trifluoperazine 2.60 100 1 1 Triflupromazine Hydrochloride 2.50 100 1 1 Tromethamine 2.52 100 Todralazine Hydrochloride 2.64 66.67 Vilazodone Hydrochloride 2.71 88.89 22 sub- total Yohimbine 3.54 61.54 17 active 5 inactive 77% agreement 2,6-di-t-butyl-4-methylphenol, Butylated 3.51 4.35 Hydroxytoluene 2-methoxyestradiol 2.83 13.33 2-thiouracil 3.33 3.7 3-methyl-1-phenyl-2-pyrazolin-5-one (mci-186), 3.16 5.56 Edaravone Acetylcholine 2.63 17.39 Adenosine Phosphate 3.21 19.05 Adiphenine Hydrochloride 3.03 16 Alfacalcidol 2.59 1.72 Alprenolol Hydrochloride, Alprenolol 3.11 6.06 Altrenogest 3.43 21.05 Amantadine 2.84 15.38 1 1 Aminohydroxybutyric Acid 4.14 5.13 Aminopterin 3.26 0 1 1 Amorolfine 2.52 8.57 Amphotericin B 4.71 6.98 1 1 Aniracetam 2.54 3.57 Antazoline 3.06 22.73 Arecoline Hydrobromide 2.50 2.17 1 1 Artenimol 3.60 6.67 Ascorbic Acid 4.33 0 Atazanavir 3.22 6.25 Azaperone 3.86 0 Azlocillin 4.15 0 Balsalazide 2.56 3.85 Barnidipine 4.12 10 Beclomethasone 4.46 17.78 Benztropine 3.29 10 Benzydamine Hydrochloride 3.91 37.5 Bergapten 3.14 18.18 Betahistine 2.90 10.53 Betaine 2.86 0 Bifonazole 2.76 22.5 Biperiden 2.84 5.45 Bismuth Subsalicylate 3.68 0 Buflomedil, Buflomedil Hydrochloride 4.19 10 Cabergoline 5.23 15.62 Capecitabine 2.47 0 Captopril 3.02 11.11 Carbetapentane Citrate 2.47 7.41 Carmofur 3.78 45.71 Cefotaxime 4.78 8.89 Cefuroxime 3.04 0 Celecoxib 2.66 28 Chenodiol 2.48 19.23 Chloramphenicol 2.71 0 Chloramphenicol Hemisuccinate, 2.64 3.85 Chloramphenicol Sodium Succinate Chlormadinone Acetate 2.49 5.56 1 1 Chloropyramine Hydrochloride 2.89 39.29 Chlorpyrifos 2.65 5 Chlortetracycline 2.90 10.53 Chlorzoxazone 2.52 3.7 Cilnidipine 4.50 25 Cilostazol 2.64 7.14 Cinnarazine 2.63 23.53 1 1 Cinromide 2.67 6.9 Ciprofibrate 2.66 2.38 Cisapride 2.85 10.71 Clobetasol Propionate 2.57 13.16 Clonazepam 4.74 0 1 1 Clonidine 2.79 4.55 Clopidogrel 2.61 11.9 Cloxacillin 2.54 9.09 colchicine 3.04 5.26 1 1 Colforsin 3.95 3.12 Cyclopentolate Hydrochloride 4.95 12 1 1 Cyproheptadine 3.49 28.57 Cysteamine Hydrochloride 2.79 12.5 Dantrolene 2.97 2.63 Dasatinib 2.67 0 Daunorubicin 4.22 25 Decoquinate 2.54 2.38 Deflazacort 2.47 3.57 Delavirdine Mesylate 4.04 15.38 Deracoxib 2.70 2.44 Desoxycorticosterone Acetate 2.57 4.17 Dexbrompheniramine, Dexbrompheniramine 3.21 10.2 Maleate Dexfenfluramine 3.34 0 Dextromethorphan Hydrobromide 4.71 32.43 Desvenlafaxine Succinate 2.47 2.7 Diaveridine 2.89 4.65 Diazoxide 4.47 11.76 Dibucaine 3.55 8 1 1 Diflorasone Diacetate 3.16 0 Dihydroergotamine Methanesulfonate, 4.25 34.78 Dihydroergotamine Mesylate Diltiazem 5.69 22.22 Diltiazem Hydrochloride 4.51 8.7 Diminazene Aceturate 5.17 14.29 Diphenidol 2.53 13.64 Doxazosin 3.45 14.29 Doxepin 3.33 20.51 Doxepin Hydrochloride 3.81 20 1 1 Drofenine Hydrochloride 2.67 40.54 Efaroxan, Efaroxan Hydrochloride 2.76 13.95 Eprobemide 3.63 3.7 Ergonovine 3.23 26.67 Ergonovine Maleate 4.90 19.35 Ergotamine 2.49 0 1 1 Erythrosine Sodium 3.94 9.09 1 1 Estradiol Cypionate 2.61 16 Ethinylestradiol 2.79 13.51 1 1 Ethynodiol Diacetate 2.82 4.26 Etomidate 2.83 6.25 Etoricoxib 2.70 8.82 Famprofazone 2.75 32.26 Fenoldopam Mesylate 2.91 0 Finasteride 3.08 10.53 Flopropione 3.29 0 flunarizine 3.23 26.32 1 1 Flutamide 6.72 5.26 Fulvestrant 3.26 11.11 Glafenine 3.01 13.64 Granisetron 3.30 5.26 Guanfacine Hydrochloride 3.60 2.27 Halcinonide 3.13 3.33 Hydroquinidine 2.80 28.57 Hydroxyamphetamine Hydrobromide 2.99 21.05 Hydroxychloroquine Sulfate 2.52 4.26 Hydroxyzine 3.07 0 Ibandronate Sodium 2.58 0 Idoxuridine 2.49 0 Imatinib, Imatinib Mesylate 3.23 43.48 Imipenem 3.18 0 iodipamide 2.63 10 1 1 Ipriflavone 6.26 11.76 Itopride, Itopride Hydrochloride 2.49 20 d M ≥ 2.47 (% degeneracy Ketamine 3.04 11.11 <50) Ketanserin Tartrate 2.57 4.17 Ketoprofen 3.81 17.24 Labetalol 2.50 13.33 Lansoprazole 2.50 0 Levobunolol 2.58 6.67 Levocarnitine 3.72 15.38 Levocetirizine Dihydrochloride 2.64 7.41 lomerizine 4.64 47.83 1 1 Lomustine 7.24 2.13 Lorazepam 3.51 4.44 Loxoprofen 3.12 2.7 L-phenylephrine 2.59 8.57 Mannitol 2.66 31.58 Melatonin 3.27 15.38 Melengestrol Acetate 3.32 31.03 Mesoridazine Besylate 2.47 2.22 Metaxalone 2.98 4 Methiothepin Mesylate, Metitepine Maleate 3.09 44.83 1 1 Methyltestosterone 3.14 14.29 Methysergide Maleate 3.48 13.64 Mexeneone 2.85 16.22 Minoxidil 3.39 4.76 Mirtazapine 3.09 15.15 Moclobemide 4.74 6.67 Moexipril Hydrochloride 2.47 8.7 Morantel Citrate 2.51 0 Moroxydine Hydrochloride 4.07 3.7 Nanofin 2.51 0 Nefopam 4.07 2.38 Nialamide 7.76 7.69 nicardipine 2.63 6.9 1 1 Nicergoline 3.27 35.29 Nifedipine 2.50 4.17 1 1 Nithiamide 2.93 8.33 Nitrazepam 3.29 7.14 Nitrofurantoin 2.71 0 Norethindrone 2.47 11.43 Norethynodrel 3.51 13.04 Norgestimate 2.98 27.59 Nylidrin 2.96 9.68 Olmesartan 4.54 0 Olmesartan Medoxomil 2.53 10.71 Ondansetron 3.62 10.71 Ornidazole 3.71 3.85 Orphenadrine 2.78 15.79 Oxiconazole 2.60 18.92 Oxymetholone 2.92 6 Panthenol 2.49 12.5 Pentetrazole, Pentylenetetrazol 2.79 11.11 Pergolide 6.20 15 1 1 Perindopril Erbumine 3.39 10 1 1 Phenacetin 2.86 2.56 Phenylpropanolamine 3.58 0 Phthalylsulfathiazole 2.57 4.17 Pidolic Acid 2.89 2.7 Pidotimod 2.64 6.67 Piperacillin Sodium 2.54 2.63 Piperidolate Hydrochloride 3.22 2.94 Pirenperone 3.31 8.33 Pralidoxime Iodide, Pralidoxime Chloride 2.63 2.94 Pramipexole 5.40 9.52 Pizotyline Malate 2.77 12.5 Prasterone 2.85 7.69 Prednicarbate 3.68 6.06 Pregnenolone Succinate 2.72 10 Pridinol 3.29 26.09 Protirelin 2.88 14.29 Proxyphylline 2.95 10 Pyrilamine 3.70 3.7 Pyronaridine Tetraphosphate 3.13 4.88 1 1 Quinidine 2.71 18.52 Quinine Sulfate 2.69 3.85 1 1 Reboxetine Mesylate 2.84 12.5 1 1 Remacemide Hydrochloride 2.65 22.73 Rifampin 2.95 22.22 Ritonavir 2.55 26.32 Salmeterol 3.14 39.29 Saquinavir 3.61 11.11 Sarafloxacin Hydrochloride 2.92 6.52 Sibutramine 2.49 28.57 Solifenacin Succinate 3.66 8.33 Spiperone Hydrochloride, Spiperone 2.57 21.62 Spironolactone 4.26 14.29 Stanozolol 2.48 22.22 Streptomycin Sulfate 2.55 6.45 Sulpiride 2.50 3.7 1 1 Taurine 3.25 5.56 Tazobactam 2.81 13.33 Telithromycin 2.48 0 tenylidone 2.61 22.22 1 1 Tepoxalin 2.58 5.88 Terconazole 2.92 7.69 Testosterone Propionate 2.49 40.62 Tetracaine 3.19 17.86 Thiamphenicol 2.52 2.7 Tolnaftate 3.01 24.14 Tolterodine 2.55 2.38 Toltrazuril 3.15 20 Topiramate 2.52 16.67 Topotecan, Topotecan Hydrochloride 2.64 5.88 Tramadol Hydrochloride 3.12 3.7 1 1 Triamcinolone Diacetate 2.57 3.45 Trihexyphenidyl 2.61 12.24 Trimetozine 2.47 2.78 Tripelennamine 2.98 14.29 Triprolidine Hydrochloride 3.39 46.15 Tropicamide 2.74 12.5 Tryptophan 2.89 16.67 Tulobuterol, Tulobuterol Hydrochloride 2.53 7.14 Tyrothricin 2.80 0 Uk 14,304 2.79 2.33 Urea 2.66 6.67 Valganciclovir Hydrochloride 2.47 12.12 Valproic Acid Sodium, Valproate Sodium 3.29 7.69 Vardenafil Hydrochloride, Vardenafil Citrate 3.70 18.75 Vatalanib Dihydrochloride 5.29 21.43 Vidarabine 3.10 30 Vinblastine Sulfate 2.92 47.62 1 1 Vincristine 2.67 20.83 Vorinostat 2.90 17.14 Xylazine Hydrochloride, Xylazine 3.09 15.38 1 1 Xylometazoline 4.88 23.08 Yohimbine Hydrochloride 3.17 17.24 30 sub-total Zafirlukast 2.83 14.63 14 active 16 inactive 47% agreement (-)-menthol, Levomenthol 2.06 100 Acrisorcin 2.25 100 Afalanine 1.70 100 Alexidine Hydrochloride 2.11 100 1 1 Algestone Acetophenide 2.18 100 Allylisothiocyanate 2.00 100 Amitriptyline 2.38 91.3 1 1 amlodipine 2.05 100 1 1 Amlodipine Besylate 1.87 100 amscarine 1.66 100 Amsulosin 2.16 100 aripiprazole 1.83 100 1 1 Astemizole 1.73 100 Benfluorex Hydrochloride 2.32 100 Benzethonium Chloride 2.09 100 Benzyl Isothiocyanate 1.91 100 Bepridil Hydrochloride 1.55 100 benzoxiquine 2.44 100 1 1 Bithionol 2.32 100 1 1 Bitoscanate 2.16 100 Bleomycin (bleomycin B2 Shown) 2.36 53.57 Bornyl Acetate 2.30 100 Bortezomib 1.73 100 Bronopol 1.99 100 1 1 broxaldine 1.75 100 1 1 Broxyquinoline
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • Combined Effects of Celecoxib and Cepharanthine on Human Colorectal Cancer Cells in Vitro
    Journal of Applied Pharmaceutical Science Vol. 9(04), pp 117-125, April, 2019 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2019.90415 ISSN 2231-3354 Combined effects of celecoxib and cepharanthine on human colorectal cancer cells in vitro Parawee Lerdwanangkun1, Piyanuch Wonganan1, Robin James Storer2, Wacharee Limpanasithikul1* 1Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 2Office of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. ARTICLE INFO ABSTRACT Received on: 11/09/2018 Colorectal cancer is one of the most common cancers worldwide. We investigated the combined effects of celecoxib Accepted on: 22/01/2019 (CLX)–cepharanthine (CEP) on HT-29 human colorectal cancer cells. CLX at 5, 10, 20, or 40 µM in combination Available online: 18/04/2019 with CEP at 1.25, 2.5, or 5 µM displayed synergistic cytotoxic effects with a combination index <1. Combinations of 20 or 40 µM of CLX with 1.25 or 2.5 µM of CEP increased HT-29 cell accumulation at the G1 phase of the cell cycle. The combined treatments increased the levels of p21 mRNA and decreased the levels of cyclin-A2 mRNA. Their Key words: combined effect triggered significant apoptosis of HT-29 cells when compared with the effect of each drug alone. The Celecoxib, cepharanthine, apoptotic effects of the drugs were correlated with increases in the levels of mRNA for BAX and decreases in the colorectal cancer, apoptosis, levels of mRNA for Bcl-xL. The results from this study revealed that at concentrations that were sub-IC individually, cell cycle.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Aldactone 50 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of Spironolactone. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (Tablets) Round, white coloured, biconvex tablet with a peppermint odour embossed ‘SEARLE over 916’ on one side and the other side plain. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Children should only be treated under guidance of a paediatric specialist. There is limited paediatric data available (see sections 5.1 and 5.2). 4.2 Posology and method of administration Administration of Aldactone once daily with a meal is recommended. Posology Adults Congestive heart failure: Usual dose - 100 mg/day. In difficult or severe cases the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 75 mg/day to 200 mg/day. Severe heart failure in conjunction with standard therapy (New York Heart Association Class III-IV): Based on the Randomized Aldactone Evaluation Study (RALES), treatment in conjunction with standard therapy should be initiated at a dose of spironolactone 25 mg once daily in patients with a serum potassium ≤5.0 mEq/L and serum creatinine ≤2.5 mg/dL. Patients who tolerate 25 mg once daily may have their dose increased to 50 mg once daily as clinically indicated.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]